Some big drugs see big changes in Q4, but most stay stable
CMS describes Q4 ASP drug prices as being “relatively stable,” and said prices for the top Part B drugs decreased by 0.4%. But some of the most utilized drugs saw big fluctuations.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.